Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Oct;26(10):2223-2230.
doi: 10.1002/ejhf.3428. Epub 2024 Aug 30.

Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial

Dirk J van Veldhuisen  1 , Michiel Rienstra  1 , Arend Mosterd  2   3 , A Marco Alings  3   4 , Antoinette D J van Asselt  5 , Marcel L Bouvy  6 , Jan G P Tijssen  7 , Jeroen Schaap  3   4 , Ernst E van der Wall  8 , Adriaan A Voors  1 , Eva M Boorsma  1 , Dirk J A Lok  9 , Harry J G M Crijns  10 , Astrid Schut  3 , Marlene A T Vijver  1 , Geert H D Voordes  1 , Agaath H de Vos  1 , Ester L Maas-Soer  1 , Nicoline W Smit  1 , Daan J Touw  11 , Michelle Samuel  1 , Peter van der Meer  1 ; DECISION Investigators and Committees
Collaborators, Affiliations
Free article
Randomized Controlled Trial

Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial

Dirk J van Veldhuisen et al. Eur J Heart Fail. 2024 Oct.
Free article

Abstract

Aims: Digoxin is the oldest drug in cardiovascular (CV) medicine, and one trial conducted >25 years ago showed a reduction in heart failure (HF) hospitalizations but no effect on mortality. However, later studies suggested that the dose of digoxin used in that trial (and other studies) may have been too high. The DECISION (Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands) trial will examine the efficacy and safety of low-dose digoxin in HF patients with reduced or mildly reduced left ventricular ejection fraction (LVEF) with a background of contemporary HF treatment.

Methods: The DECISION trial is a randomized, double-blind, parallel-group, placebo-controlled event-driven outcome trial which will investigate the efficacy and safety of low-dose digoxin in patients with chronic HF and LVEF <50%. Both patients with sinus rhythm and atrial fibrillation will be enrolled and will be randomized (1:1) to low-dose digoxin or matching placebo. To maintain a target serum digoxin concentration of 0.5-0.9 ng/ml, dose adjustments are made throughout follow-up based on serum digoxin measurements with dummy values for the placebo group. The primary endpoint is a composite of CV mortality and total HF hospitalizations or total urgent hospital visits for worsening HF, and all endpoints are adjudicated blindly by a Clinical Event Committee. The estimated sample size was 982 patients who will be followed for a median of 3 years, and in December 2023 enrolment was completed after 1002 patients.

Conclusions: The DECISION trial will provide important evidence regarding the effect of (low-dose) digoxin on CV mortality and total HF hospitalizations and urgent hospital visits when added to contemporary HF treatment of patients with reduced or mildly reduced LVEF.

Clinical trial registration: ClinicalTrials.gov identifier: NCT03783429.

Keywords: Digoxin; Heart failure; Hospitalizations; Low‐dose; Mortality; Randomized clinical trial.

PubMed Disclaimer

References

    1. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006;113:2556–2564. https://doi.org/10.1161/CIRCULATIONAHA.105.560110
    1. Ziff OJ, Kotecha D. Digoxin: The good and the bad. Trends Cardiovasc Med 2016;26:585–595. https://doi.org/10.1016/j.tcm.2016.03.011
    1. Bavendiek U, Davilla LA, Koch A, Bauersachs J. Assumption versus evidence: The case of digoxin in atrial fibrillation and heart failure. Eur Heart J 2017;38:2095–2099. https://doi.org/10.1093/eurheartj/ehw577
    1. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–533. https://doi.org/10.1056/NEJM199702203360801
    1. Remme WJ, Swedberg K; Task Force for the Diagnosis and Treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527–1560. https://doi.org/10.1053/euhj.2001.2783

Publication types

MeSH terms

Associated data